Latest Conference Coverage

AAN Annual Meeting 2023: Top Expert Interviews

A group of experts in the care of patients with neurological conditions—Ali Jannati, MD, PhD; Madhav R. Thambisetty, MD, PhD; Daniel Ontaneda, MD, PhD; Peter J. Goadsby, MD, PhD, DSc; Andrew Russman, DO—shared their perspectives on hot topics of treatment and management in neurology from the 2023 American Academy of Neurology Annual Meeting.

Serial Assessments Used in Groundbreaking Brain Study: Imad Najm, MD

The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute provided perspective on the in-depth testing neurologically healthy patients in the Brain Study will undergo. [WATCH TIME: 3 minutes]

Recombinant Human Growth Hormone, Testosterone Improves Ambulation, Disease Burden in Facioscapulohumeral Muscular Dystrophy

Total disease burden, measured by the Facioscapulohumeral Muscular Dystrophy Health Index, was reduced by 19% over a 24-week period on recombinant human growth hormone.

Future Research Directions for DCTclock and the Potential to Predict Alzheimer Biomarkers: Ali Jannati, MD, PhD

The manager of Clinical Development-Research at Linus Health discussed potential avenues of research for the DCTclock and expanding its capabilities as a potential detector of cognitive decline. [WATCH TIME: 3 minutes]

Mediterranean Diet Demonstrates Significant Positive Impacts on Cognition in Multiple Sclerosis

Higher adherence to Mediterranean Diet Adherence Screener independently predicted 20% lower risk for cognitive impairment among patients with MS.

Recapping Research From 2023 AAN Annual Meeting

As a recap from AAN 2023, get caught up on some of the latest news in neurology as the NeurologyLive® team shares some of our data updates.

A Comprehensive Analysis of Stroke Prevalence Among Adults in the United States: Wells Andres, MD

The neurology resident from the University of Pennslyvania talked about stroke prevalence in the United States between 1999 and 2018 as part of a presentation at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]

Zavegepant Effective in Acute Migraine Regardless of Aura Presence

A statistically significantly higher proportion of patients, both with and without predose aura, achieved 2-hour relief of the most bothersome symptom with zavegepant.

Initiating Difficult Conversations With Patients Based on Hard Data: Daniel Ontaneda, MD, PhD

The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine of Case Western University provided commentary on the need for clinicians to be transparent with patients with MS about potential differences in disease course. [WATCH TIME: 3 minutes]

Atogepant's Impact on Chronic Migraine, LD/CD Intra-Oral Pump Improves ON Time, Ravulizumab Effective in NMOSD Subgroups

Neurology News Network for the week ending April 30, 2023. [WATCH TIME: 4 minutes]

ANX005 Demonstrates Safety in Huntington Disease, With Improvements Found in Subgroups of Patients

In a subgroup of individuals with Huntington disease with high baseline C4a/C4 levels, treatment with ANX005 resulted in significant improvement in composite Unified Huntington’s Disease Rating Scale across all timepoints.

NeurologyLive® Clinician of the Month Spotlight: Michelle Mauermann, MD

In April 2023, NeurologyLive® is spotlighting a clinician in neuromuscular diseases, Michelle Mauermann, MD, chair of the division of neuromuscular medicine at Mayo Clinic.

Cognitive Performance in Pediatric Multiple Sclerosis

Kimberly O’Neill, MD, pediatric neuroimmunology fellow at NYU Langone, discussed her presentation at the 2023 AAN Annual Meeting focused on cognitive similarities between pediatric and adult MS.

Efforts to Grow Neurology and Attract Young Medical Professionals to the Field: John Greenfield, MD, PhD

The president elect of the Association of University Professors of Neurology discussed the benefits of working in neurology and the ways to not only attract new clinicians, but keep those already in the field. [WATCH TIME: 3 minutes]

Clinical Research in ALS, the Potential of CNM-Au8 in the Care Landscape: James Berry, MD, MPH

The director of the Massachusetts General Hospital ALS Care Center discussed the importance of effective disease-modifying therapies for ALS and the potential of CNM-Au8 in the management of the disease. [WATCH TIME: 2 minutes]

Pridopidine Shows Clinically Meaningful Results in Huntington Disease for Patients Not on Neuroleptics, Chorea Medications

Q-Motor, an objective measure of motor function, showed robust beneficial effects for individuals treated with pridopidine in PROOF-HD at various time points.

Imad Najm, MD, on the World Brain Study After 1 Year

The director of Cleveland Clinic's Epilepsy Center at the Cleveland Clinic Neurological Institute shared his insight into the findings of the World Brain Study, 15 months after its initiation.

Serum Ravulizumab Concentrations Maintained Above Therapeutic Threshold in AQP4+ NMOSD

Inhibition of serum free complement 5 with ravulizumab was sustained throughout the treatment period according to a pharmacokinetics and pharmacodynamics analysis.

EEG as a Diagnostic Tool for Mild Cognitive Impairment: Andrew Budson, MD

The professor of neurology at Boston University Chobanian & Avedisian School of Medicine talked about diagnostic tools and using memory aids for patients with cognitive impairment at the 2023 AAN Annual Meeting. [WATCH TIME: 7 minutes]

Leriglitazone Demonstrates Lesion Growth Deceleration in Pediatric Cerebral Adrenoleukodystrophy

Minoryx's leriglitazone showed a decrease in matrix metalloproteinase-9 concentrations in pediatric patients with cerebral adrenoleukodystrophy, according to a 24-week analysis.

Postictal Generalized EEG Suppression as a Biomarker for SUDEP: Nancy R. Foldvary-Schaefer, DO, FAAN

The director of the Sleep Disorders Center and staff in the Epilepsy Center at Cleveland Clinic discussed how additional sensors in seizure monitoring for patients with epilepsy may help better manage the risk of SUDEP. [WATCH TIME: 3 minutes]

Remaining Questions and Next Steps for Parkinson Agent P2B001: Lawrence Elmer, MD, PhD; Cheryl Fitzer-Attas, PhD

The medical director of the Center for Neurological Disorders at the University of Toledo discussed positive phase 3 findings assessing P2B001, and how the agent would potentially fit in the Parkinson treatment landscape. [WATCH TIME: 4 minutes]

Phase 3 NEURO-TTRansform Findings Signify Eplontersen as Promising Agent for hATTR Polyneuropathy

After 66 weeks of treatment, patients on eplontersen showed sustained reduction in TTR concentration, halted progression of neuropathy impairment, and improved quality of life.

Understanding Reasons for Greater Disability, Loss of Deep Gray Matter in Latinx Patients With MS: Daniel Ontaneda, MD, PhD

The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine of Case Western University discussed a presentation at AAN 2023 characterizing the clinical and MRI features of Latinx with multiple sclerosis. [WATCH TIME: 4 minutes]

Phase 3 PROGRESS Results Highlight Atogepant’s Benefit in Chronic Migraine

In comparison with placebo, atogepant 30 mg twice daily and 60 mg once daily resulted in greater reductions in monthly migraine days, as well as proportion of patients with at least 50% reduction in 3-month average of MMDs.

Todd Levine, MD, on the Syn-One Test and Its Role in Neurodgenerative Disorder Diagnosis

The chief medical officer and cofounder of CND Life Sciences, who served as principal investigator of the study, offered insight into the Syn-ONe Test's clinical utility.

Oral Levodopa/Carbidopa Pump May Improve ON/OFF Time in Parkinson Disease

The pump, attached to a wearable retainer, continuously delivers the liquid medication with little to no adverse effects.

Ravulizumab Superior in Preventing On-Trial Relapse in Subgroups of NMOSD

The treatment was superior in preventing on-trial relapse in both the monotherapy and immunosuppressive therapy groups compared with placebo in the CHAMPION-NMOSD trial.

Impressive Response Rates for Patients in Migraine Prevention Study: Peter J. Goadsby, MD, PhD, DSc

The professor of neurology at King’s College, London, spoke about the phase 3 ELEVATE trial investigating atogepant for episodic migraine at the 2023 AAN Annual Meeting. [WATCH TIME: 5 minutes]

Effectiveness of Minimally Invasive Parafascicular Surgery in Intracerebral Hemorrhage: Andrew Russman, DO

The head of the Stroke Program and Medical Director of the Comprehensive Stroke Center at Cleveland Clinic provided perspective on the ENRICH trial, the first positive surgical trial for intracerebral hemorrhage. [WATCH TIME: 5 minutes]